Drug Repurposing: FDA IND Authority Lacks Levers To Better Direct Trial Resources In A Pandemic

Office of New Drug Director Peter Stein says there needs to be a better way to facilitate drug repurposing to avoid wasting time and resources on theories with little scientific probability of success.